CDIO - MCAP CO - Cardio Diagnostics

Cardio Diagnostics (CDIO) develops AI-driven tests for the early detection of cardiac pathologies, expanding its market reach through US insurers and clinics. The implementation of partnerships to deploy genetic platforms is already yielding results, and the market capitalization on the price chart stands at 0.01. This business relies on the defensive qualities of diagnostics, as heart attack prevention remains in demand across any economic cycle, ensuring inflation resistance.

Market capitalization reflects the aggregate value of all Cardio Diagnostics (CDIO) shares, determining the scale of the business in real time. This metric is calculated as the product of the current share price and the number of outstanding shares. By analyzing the company's valuation on the stock market, an investor can observe the price action in response to corporate events. Strong pricing power in preventive cardiology supports this indicator, while the synergy of AI and genetics ensures the stability of the capitalization.